Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Biomanufacturing Technology and Partnership (BioTAP) Funding Initiative

    Limited submission

    Biomanufacturing Technology and Partnership (BioTAP) Funding Initiative supports Singapore public-sector researchers developing biomanufacturing processes and capabilities for GMP readiness and industry adoption.

    OverviewSimilar Grants
    OverviewSimilar Grants

    Funder: Agency for Science Technology and Research (A*STAR)

    Due Dates: January 8, 2027, 5:00pm Singapore time (Submission)

    Funding Amounts: Seed: up to S$500,000 for 12–18 months | Core: up to S$5 million for up to three years (including overheads)

    Summary: Supports Singapore public-sector research advancing biomanufacturing processes, enabling technologies and CMC capabilities towards GMP readiness and industry adoption.

    Key Information: Institutional submission quotas apply, and projects must commit to industry R&D spending and/or industry partnership KPIs.


    Description

    The Biomanufacturing Technology and Partnership (BioTAP) Funding Initiative is an RIE2030 initiative implemented by A*STAR to strengthen Singapore’s competitiveness in biopharma manufacturing across conventional and emerging therapeutic modalities. It connects public-sector research with industry needs through research, translation and capability development, including process optimisation, digitalisation, sustainability and manufacturing technology innovation.

    The first call, Accelerate Translation & GMP Readiness, supports pre-GMP process development and piloting, alongside Chemistry, Manufacturing and Controls (CMC) know-how and analytical capability development. It targets manufacturing bottlenecks and translational risks through scalable processes, manufacturing-relevant demonstrations, product characterisation, quality assurance and reusable tools or platforms. The emphasis is on evidence and capabilities supporting subsequent GMP implementation, clinical development and industry adoption—not a requirement to execute GMP manufacturing itself. Broadly applicable capabilities benefiting multiple products or industry stakeholders are particularly encouraged.


    Atom

    See the full grant listing

    Sign in to view full eligibility details, sources, similar grants, and AI-powered analysis.